[Verification of desferrioxamine ototoxicity by high-frequency audiometry in patients undergoing dialysis].
The AA. have studied the Desferrioxamine ototoxicity with high frequency audiometry (HFA), given the drug as a test for diagnosis of aluminium-related done disease in patients under dialysis. The dose of 10 mg/kg presents high sensitivity and low ototoxicity.
Martín
C
C
Hospital General De Galicia, Facultad de Medicina, Universidad de Santiago, Santiago de Compostela.
Lens
X M
XM
Prieto
A
A
Alonso
R
R
Correa
B
B
Arcocha
V
V
Soto
A
A
D000328:Adult; D000535:Aluminum / Q000032:analysis / Q000097:blood* / Q000378:metabolism; D001299:Audiometry; D001847:Bone Diseases / Q000378:metabolism / Q000628:therapy*; D003676:Deferoxamine / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D005260:Female; D006311:Hearing Disorders / Q000175:diagnosis / Q000209:etiology*; D006801:Humans; D007231:Infant, Newborn; D008297:Male; D008875:Middle Aged; D006435:Renal Dialysis
D000535:Aluminum; D003676:Deferoxamine
Determinación de la ototoxicidad por desferrioxamina por audiometría de alta frecuencia en enfermos sometidos a diálisis.